Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026727 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
A Phase 2 study, sponsored by Myrexis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01026727 is a Phase 2 study that was terminated before completion, run by Myrexis. The registered enrollment target is 2 participants.
The verdict
NCT01026727, a Phase 2 study, was terminated before completion, sponsored by Myrexis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment experienced, HIV-1 infected subjects.
Interventions
- DRUG MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
- DRUG 3-4 commercially available antiretroviral drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026727
The ClinicalTrials.gov registry entry for NCT01026727 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MPC-4326 plus a 2-3 drug optimized background regimen (OBR) is the first listed.
NCT01026727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026727 about?
NCT01026727 is a clinical study titled "A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy". This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment experienced, HIV-1 infected subjects.
What is the current status of trial NCT01026727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01026727?
The interventions under investigation include: MPC-4326 plus a 2-3 drug optimized background regimen (OBR) (DRUG), 3-4 commercially available antiretroviral drugs (DRUG).
Who is sponsoring clinical trial NCT01026727?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.